Prosecution Insights
Last updated: November 20, 2026
Application No. 18/459,729

MULTIPLEX EDITING WITH CAS ENZYMES

Final Rejection §112
Filed
Sep 01, 2023
Priority
Mar 19, 2021 — provisional 63/163,510 +4 more
Examiner
CHONG, KIMBERLY
Art Unit
1636
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Metagenomi Therapeutics Inc.
OA Round
2 (Final)
72%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
1092 granted / 1508 resolved
+12.4% vs TC avg
Moderate +13% lift
Without
With
+13.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
52 currently pending
Career history
1577
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
31.3%
-8.7% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
33.2%
-6.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1508 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Application/Amendment/Claims Applicant's response filed 08/10/2026 has been considered. Rejections and/or objections not reiterated from the previous office action mailed 05/14/2026 are hereby withdrawn. The following rejections and/or objections are either newly applied or are reiterated and are the only rejections and/or objections presently applied to the instant application. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. With entry of the amendment filed on 08/10/2026, claims 74, 75, 77-81, 83-85 and 94-103 are pending and currently under examination. Claims 1-73, 76, 82 and 86-93 have been canceled. SEQ ID Nos. 3, 10-13 and 62 are free of the prior art searched. The 102 and 103 rejections are withdrawn in response to claim amendments. The amendment to the Specification and new Sequence Listing is accepted. New Claim Rejections – necessitated by claim amendments Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 77 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 77 recites “a nucleic acid comprising a sequence having at least 85% sequence identity to SEQ ID No. 62. Claim 77 depends from claim 74 which recites “a nucleic acid comprising a sequence having at least 90% sequence identity to SEQ ID No. 62 and therefore claim does not limit claim 74. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Maintained Rejections Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. Written Description Claims 74, 75, 77, 78, 80, 83-85 and 94-103 remain rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. Applicant’s arguments have been considered but are not found persuasive. Applicant argues claim 74 is herein amended to recite, in part, "a first class 2, type II Cas endonuclease... encoded by a nucleic acid comprising a sequence having at least 90% sequence identity to SEQ ID NO: 62; and a first engineered guide ribonucleic acid ...wherein said first engineered guide ribonucleic acid comprises a sequence having at least 90% sequence identity to SEQ ID NO: 3." Applicant respectfully submits that claim 74, as amended herein, is sufficiently disclosed by the instant Specification to convey to the skilled artisan that the Applicant has possession of the claimed subject matter at the time of filing. For example, the instant Specification as filed at, inter alia, paragraphs [0007], [0013] and [0016] provides for a "first... class 2, type II Cas endonuclease... [and a] first engineered guide RNA...having at least 80%, 85%, 90%, or 95% sequence identity to any one of SEQ ID NOs: 3, 6, or 9" in combination with a second class 2, type II Cas endonuclease and a second engineered guide RNA. See instant Specification at par. [0016]. In addition, FIG. 10 shows "multiplex TRAC/TRBC editing in primary T cells" with a first class 2, type II Cas endonuclease that is encoded by a nucleic acid comprising a sequence having at least 90% sequence identity to SEQ ID NO: 62 and a second class 2, type II Cas endonuclease, as claimed. See instant Specification at par. [0029]. The claims as amended are still drawn to a first class 2 type II Cas endonuclease encoded by a nucleic acid having at least 85%, 90% or 95% sequence identity to SEQ ID No. 62, a second class 2 type II Cas endonuclease or any nucleic acid encoding a second class 2 type II Cas endonuclease and a second class 2 type II Cas endonuclease having 85% sequence identity to SEQ IID No. 4. The amendment "a first class 2, type II Cas endonuclease... encoded by a nucleic acid comprising a sequence having at least 90% sequence identity to SEQ ID NO: 62” is not efficient to provide adequate written description. Given the substantial size of some of the claimed encoded Cas endonuclease having sequence identity of 85%- 95% SEQ ID No. 62, a second class 2 type II Cas endonuclease or any nucleic acid encoding a second class 2 type II Cas endonuclease and a second class 2 type II Cas endonuclease having 85% sequence identity to SEQ IID No. 4, these encompasses extensive sequence variations. The breadth of the claimed genera described above encompasses a wide range of possible structural variants and while the specification does disclose a few variants of the encoded Cas endonuclease (e.g., MG3-6 protein having 1132 amino acids Example 5 used in Fig. 10 results and MG3-8 protein of 1132 amino acids), it does not identify any essential or critical residues, nor does it describe which amino acid and/or nucleotide changes (substitutions, insertions, or deletions) of nucleic acid having at least 85%-95% sequence identity of SEQ ID No. 62 or a second class 2 type II Cas endonuclease or any nucleic acid encoding a second class 2 type II Cas endonuclease and a second class 2 type II Cas endonuclease having 85% sequence identity to SEQ IID No. 4 that can be made, and still result in having the desired activity/function. As such, while the specification defines some species falling within the genus, it fails to define any structural features commonly possessed by members of the genus that distinguish them from others. There is no guidance that would allow a skilled artisan to predict which sequences within the claimed scope would retain the required functional activity. Further as stated previously, the prior art does not appear to provide written description to support the broad genus of Cas proteins. The prior art of Koonin et al. ("Diversity, classification and evolution of CRISPR-Cas systems." Current opinion in microbiology 37 (2017): 67-78 of record 892 mailed 05/14/2026) teach there are numerous different Cas proteins from numerous different organisms (see Figure 1). Koonin et al. illustrates each has different structures based on the different class systems (see Figure 1 and Figure 3). The prior art teaches that the PAM sequence recognized by a Cas protein, such as Cas9, must be determined experimentally for each protein variant (Karvelis et al. Methods, Vol. 121-122, pages 3-8, March 24, 2017; e.g., Abstract of record 892 mailed 05/14/2026). The prior art teaches that orthologs of a single type of Cas protein, such as Cas9, do not all share a common PAM sequence (See Beck et al. US Patent Application Publication No. 2019/0249200 A1; e.g., Table A and Fig. 1 of record 892 mailed 05/14/2026). Thus the prior art does not teach functional characteristics coupled with a known or disclosed correlation between functional and structure of Cas proteins. Since the disclosure and the prior art fail to describe the common attributes and characteristics concisely identifying members of the proposed genus, and because the claimed genus is highly variant a vast number of nucleic acid sequences and endonuclease sequences, one of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species to describe the genus claimed. Regarding amended claim 78 reciting a first class 2 type II Cas endonuclease comprising SEQ ID No. 62, the claim depends from claim 74 which still comprises using any a second class 2 type II Cas endonuclease or any nucleic acid encoding a second class 2 type II Cas endonuclease which is not adequately described as discussed above. Regarding amended claim 79 reciting a second class 2 type II Cas endonuclease comprising SEQ ID No. 62, the claim depends from claim 74 which still comprises a first class 2, type II Cas endonuclease encoded by a nucleic acid comprising a sequence having at least 90% sequence identity to SEQ ID NO: 62 which is not adequately described as discussed above. Regarding claim 80 amended to recite the first engineered guide RNA comprises a sequence having 95% sequence identity to SEQ ID No 3, claim 80 depends from claim 74 which still comprises a first class 2, type II Cas endonuclease encoded by a nucleic acid comprising a sequence having at least 90% sequence identity to SEQ ID NO: 62 which is not adequately described as discussed above. Regarding claim 81 amended to recite the first engineered guide RNA comprises a sequence of SEQ ID No 3, claim 81 depends from claim 74 which still comprises a first class 2, type II Cas endonuclease encoded by a nucleic acid comprising a sequence having at least 90% sequence identity to SEQ ID NO: 62, any second class 2 type II Cas endonuclease or any nucleic acid encoding a second class 2 type II Cas endonuclease, any second guide RNA and any sequence spacer sequence which is not adequately described as discussed above. Regarding claim 84, the claim depends from claim 74 which still comprises a first class 2, type II Cas endonuclease encoded by a nucleic acid comprising a sequence having at least 90% sequence identity to SEQ ID NO: 62, any second class 2 type II Cas endonuclease or any nucleic acid encoding a second class 2 type II Cas endonuclease, any second guide RNA and any sequence spacer sequence which is not adequately described as discussed above. Regarding claim 94, the amended claim depends from claim 74 which still comprises a first class 2, type II Cas endonuclease encoded by a nucleic acid comprising a sequence having at least 90% sequence identity to SEQ ID NO: 62, any second guide RNA and any sequence spacer sequence which is not adequately described as discussed above. Regarding claim 95, the amended claim depends from claim 74 which still comprises a first class 2, type II Cas endonuclease encoded by a nucleic acid comprising a sequence having at least 90% sequence identity to SEQ ID NO: 62 and any sequence spacer sequence which is not adequately described as discussed above. Regarding claim 96, the amended claim depends from claim 74 which still comprises a first class 2, type II Cas endonuclease encoded by a nucleic acid comprising a sequence having at least 90% sequence identity to SEQ ID NO: 62, any second class 2 type II Cas endonuclease, any second guide RNA and any sequence spacer sequence which is not adequately described as discussed above. The remaining dependent claims remain rejected as they depended from a rejected base claim. Enablement Claims 74, 75, 77-81, 83-85 and 94-103 remain rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph. Applicant’s arguments have been considered but are not found persuasive. Applicant argues claim 74 is herein amended to recite, in part, "a first class 2, type II Cas endonuclease... encoded by a nucleic acid comprising a sequence having at least 90% sequence identity to SEQ ID NO: 62; and a first engineered guide ribonucleic acid ...wherein said first engineered guide ribonucleic acid comprises a sequence having at least 90% sequence identity to SEQ ID NO: 3." Applicant respectfully submits that claim 74, as amended herein, provides sufficient detail for one skilled in the art to make and use the invention without undue experimentation. For example, the instant Specification as filed at, inter alia, paragraphs [0098], [0099], [00102], [00103], and [00106], as well as FIGs. 10, 13, 14, and 17, provides working examples of "editing two or more loci...comprising... a first class 2, type II Cas endonuclease that is encoded by a nucleic acid comprising a sequence having at least 90% sequence identity to SEQ ID NO: 62... [and] a second class 2, type II Cas endonuclease," as claimed. Further, one of ordinary skill in the art would understand that it is possible to combine the first class 2, type II Cas endonuclease and first engineered guide ribonucleic acid having the sequences specified in claim 74 with a second class 2, type II Cas endonuclease and second engineered guide ribonucleic acid with a reasonable expectation of success of editing two or more loci within a cell without any undue experimentation. Thus, in light of the general state of the knowledge of the CRISPR-Cas field, the specifically claimed first class 2, type II Cas endonuclease and the first engineered guide ribonucleic acid, the disclosure in the instant Specification as filed "reasonably provide[s] enablement for methods of editing two or more loci" and enables a "person skilled in the art...to make and use the invention commensurate in scope with" claim 74 and the claims depending therefrom without undue experimentation. As stated previously, the claimed invention, while being enabling for methods of editing two and three different loci using MG3-6 Cas 9 endonuclease with specific sgRNA targeted to the different loci, does not reasonably provide enablement for methods of editing two or more loci using the vast number of differently sized and types of class 2 type II Cas endonucleases and different guide RNA. The broadest reasonable interpretation of the claimed method is editing two or more different loci in any cell using a vast number of different class 2 type II Cas endonuclease sequences and differently sized gRNA to any target. Enbo et al. ("Single-stranded DNA cleavage by divergent CRISPR-Cas9 enzymes." Molecular cell 60.3 (2015): 398-407 of record cited on 892 mailed 11/18/2024) describes divergent class 2 type II Cas9 enzymes and illustrates how each are structurally different (see Figure B below). Enbo et al. further highlights the differences in cleavage activity between different Cas9 enzymes in Figure E. This represents the general knowledge of the CRISPR-Cas field as it relates to just one type of Cas endonuclease. A review of the prior art does not predictably provide evidence that using any size and type of Cas endonuclease along with any gRNA can be used to edit any number of loci in any cell. The breadth of the claimed genera of Cas endonucleases encompasses a wide range of possible structural variants and while the specification does disclose a few variants of the encoded Cas endonuclease (e.g., MG3-6 protein having 1132 amino acids Example 5 used in Fig. 10 results and MG3-8 protein of 1132 amino acids), it does not identify any essential or critical residues, nor does it describe which amino acid and/or nucleotide changes (substitutions, insertions, or deletions) of nucleic acid having at least 85%-95% sequence identity of SEQ ID No. 62 or a second class 2 type II Cas endonuclease or any nucleic acid encoding a second class 2 type II Cas endonuclease and a second class 2 type II Cas endonuclease having 85% sequence identity to SEQ IID No. 4 that can be made, and still result in having the desired activity/function. As stated previously, the working embodiment in the instant application describes using methods of editing two and three different loci using MG3-6 Cas 9 endonuclease with specific sgRNA targeted to the different loci. The working embodiments do not describe the method using the vast number of different endonuclease and gRNA sequences. The standard of an enabling disclosure is not the ability to make and test if the invention works but one of the ability to make and use with a reasonable expectation of success. A patent is granted for a completed invention, not the general suggestion of an idea (MPEP 2164.03 and Chiron Corp. v. Genentech Inc., 363 F.3d 1247, 1254, 70 USPQ2d 1321, 1325-26 (Fed. Cir. 2004). The instant invention suggests methods of editing two or more loci in a cell without an enabling disclosure or guidance in the prior art describing how to make or use any number of different endonuclease and sgRNA sequences. The prior art is undeveloped for the role all the different sequences and functions of class 2 type II Cas nucleases plays in gene editing along with different sequences of gRNA and without further guidance, one of skill in the art would have to practice a substantial amount of trial and error experimentation, an amount considered undue and not routine, to practice the instantly claimed invention. Closest prior art SEQ ID No. 3 is described in the instant specification as a MG3-6 sgRNA. The specification describes generating genomic fragments from metagenomes for Type V-A nucleases and generating sgRNA for use in CRISPR-Cas systems (0071). The prior art does not teach or make obvious SEQ ID No. 3 in the claimed composition comprising the SEQ ID Nos. of a first Cas endonuclease as well as the claimed sgRNA and spacer sequences. SEQ ID No. 4 is described in the specification as a Cas endonuclease and the prior art teach a Cas endonuclease 100% identical to the claimed sequence (SEQ ID No. 423 in Thomas et al. Patent 10,982,200 of record) but do not teach or make obvious the claimed composition comprising the SEQ ID Nos. of a first and second Cas endonuclease as well as the claimed sgRNA and spacer sequences. SEQ ID No. 62 is described in the instant specification as a nucleic acid encoding MG3-6 endonuclease. Thomas et al. (Patent 10,982,200 of record) teach a sequence having 60% sequence identity to SEQ ID No. 62 (SEQ ID No. 5590) which is described as a nucleic acid sequence encoding a Cas endonuclease (col. 11). Thomas et al. does not teach the claimed sequence or make obvious reasons to extend the sequence to encompass at least 85% -100% sequence identity to SEQ ID No. 62. SEQ ID No. 10-13 are described in the instant specification as a spacer sequences however the prior art does not teach or make obvious SEQ ID No. 10 in combination with composition as claimed. Liu et al. ("CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells." Cell research 27.1 (2017): 154-157) teach a method of editing multiple genes in CAR-T cells comprising introducing a Cas9 nuclease and guide RNAs engineered to target two (TRAC and B2M) or three genes TRAC, B2M and PD-1) each configured to specifically target each target loci (see page 154 and 155), wherein the editing was quantified by tracking of indels (page 154 last para.). Liu et al. do not teach or make obvious the claimed method comprising the SEQ ID Nos. of a Cas endonuclease and a second Cas endonuclease as well as the claimed sgRNA sequences. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). 706.07(a) Final Rejection, When Proper on Second Action [R-07.2015] PNG media_image1.png 18 19 media_image1.png Greyscale Second or any subsequent actions on the merits shall be final, except where the examiner introduces a new ground of rejection that is neither necessitated by applicant’s amendment of the claims, nor based on information submitted in an information disclosure statement filed during the period set forth in 37 CFR 1.97(c) with the fee set forth in 37 CFR 1.17(p). Where information is submitted in an information disclosure statement during the period set forth in 37 CFR 1.97(c) with a fee, the examiner may use the information submitted, e.g., a printed publication or evidence of public use, and make the next Office action final whether or not the claims have been amended, provided that no other new ground of rejection which was not necessitated by amendment to the claims is introduced by the examiner. See MPEP § 609.04(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KIMBERLY CHONG at 571-272-3111. The examiner can normally be reached Monday thru Friday 9-5 pm. If attempts to reach the examiner by telephone are unsuccessful please contact the SPE for 1636 Neil Hammell at 571-272-5919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO’s Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO’s Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO’s PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see http://pair-direct.uspto.gov. For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199. /KIMBERLY CHONG/Primary Examiner, Art Unit 1636
Read full office action

Prosecution Timeline

Sep 01, 2023
Application Filed
May 14, 2026
Non-Final Rejection mailed — §112
Aug 10, 2026
Response Filed
Nov 06, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797405
COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOF
11m to grant Granted Nov 17, 2026
Patent 12790596
HSD17B13 VARIANTS AND USES THEREOF
4y 2m to grant Granted Nov 10, 2026
Patent 12790609
COMPLEX FOR TREATING OPTIC NERVE DISEASE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
3y 5m to grant Granted Nov 10, 2026
Patent 12773422
Blockade of miR466l-3p binding to IL-17A mRNA with site-specific target site blocker prevents neuro-inflammatory-mediated disease
3y 4m to grant Granted Oct 27, 2026
Patent 12767947
CHANNEL MODULATORS
4y 2m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
72%
Grant Probability
86%
With Interview (+13.1%)
2y 6m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1508 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month